Morning Overview on MSN
First human trial tests gene therapy aimed at reversing cellular aging
For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.
In this excerpt from “We Are As Gods: A Survival God for the Age of Abundance,” authors Peter H. Diamandis and Steven Kotler ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...
The idea that cells could be reset emerged from decades of research in regenerative medicine. The field traces back to 1962, ...
Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
Life runs on information. In living systems, that information takes two main forms: the genome and the epigenome. The genome stays mostly stable. The epigenome, however, constantly shifts, shaped by ...
Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...
Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...
The company described the round as fully subscribed and said the cash should keep operations running into the second half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results